Eptifibatide

Eptifibatide is a synthetic, low molecular weight glycoprotein IIb/IIIa receptor antagonist. It is also known as an integrin receptor antagonist, which means that it inhibits the binding of fibrinogen to the glycoprotein IIb/IIIa receptor on the surface of platelets.
Eptifibatide, marketed under the brand name Integrilin, is used as an adjunct to percutaneous transluminal coronary angioplasty (PTCA) and coronary artery stenting to reduce the risk of cardiac ischemic complications in patients with unstable angina/non-Q-wave myocardial infarction (MI) undergoing these procedures. It is also used as a treatment for patients with acute coronary syndrome (ACS) to reduce the risk of ischemic events, such as MI and cardiac death.
Eptifibatide is administered as an intravenous infusion, usually starting before the PTCA or coronary artery stenting procedure. The typical dosage is 180 mcg/kg as an initial bolus, followed by a 2 mcg/kg per minute infusion for up to 72-96 hours. The duration of infusion may vary depending on the clinical condition of the patient and the healthcare professional’s discretion.
Patients receiving eptifibatide should be closely monitored for potential side effects, which may include bleeding, thrombocytopenia, and an increased risk of infection. It is important to avoid concomitant use of other anticoagulant or antiplatelet agents to reduce the risk of excessive bleeding. As with any medication, patients should consult with their healthcare provider to determine the most appropriate treatment plan for their individual circumstances.